Contracts Finder

NHS Midland & East Branded Medicines, Tranche B & Annual Tranche

NHS England

Awarded
goods
SME-friendly

This tender has closed

The submission deadline for this contract has passed. There may be more active goods tenders from NHS England, and hundreds more across the UK public sector.

Key details

Contracting authority
NHS England
nhs
Region
Runcorn
Sector
Healthcare & Medical
Contract value
£480,429,000ex VAT
Submissions closed
25 October 2022
Published
15 March 2023

Procurement

Contract period
1 March 2023 - 28 February 2025
2 years
Procedure type
Open procedure (above threshold)
CPV classifications
  • 33600000 Pharmaceutical products

What happened

NHS England awarded this contract to Sandoz Ltd | Teva UK Limited | Roche Products Ltd | Kent Pharma Ltd | UL Global Pharma | Celltrion Healthcare United Kingdom Limited | Merck Sharpe & Dohme (UK) Limited | Amgen Ltd | Mylan | Thornton and Ross Ltd | Janssen-Cilag Ltd | Bayer Plc | Accord-UK Ltd | Pfizer Ltd | GlaxoSmithKline UK Limited | Abbvie Ltd | Neon Healthcare Ltd | AstraZeneca | Aventis Pharma ltd t/a Sanofi | Ipsen | Biogen | Takeda UK Ltd | Merck Serono Limited | Organon Pharmaceuticals UK Ltd | Zentiva Pharma UK Ltd | Novo Nordisk | Novartis Pharmaceuticals UK Ltd | Eli Lilly & Company Ltd | CST Pharma Limited | Gilead Sciences Limited | Gedeon Richter UK Ltd | Sobi (Swedish Orphan Biovitrum Ltd) | Almirall | Typharm Ltd | UCB Pharma Ltd (primary) worth £480,429,000 on 13 Feb 2023. The contract runs until 28 Feb 2025.

Description

NHS Framework for Midlands and East Branded Medicines - Tranche B and Annual Tranche.

Offer reference number: CM/PHR/20/5608

CM/PHR/20/5608/01 - NHS Framework for Midlands and East Branded Medicines - Tranche B. Period of framework: 1 March 2023 to 28 February 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months

CM/PHR/20/5608/02 - NHS Framework for Midlands and East Branded Medicines - Annual Tranche. Period of framework: 1 March 2023 to 29 February 2024 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months

Awarded suppliers (35)

Suppliers
  • Sandoz Ltd
  • Teva UK Limited
  • Roche Products Ltd
  • Kent Pharma Ltd
  • UL Global Pharma
  • Celltrion Healthcare United Kingdom Limited
  • Merck Sharpe & Dohme (UK) Limited
  • Amgen Ltd
  • Mylan
  • Thornton and Ross Ltd
  • Janssen-Cilag Ltd
  • Bayer Plc
  • Accord-UK Ltd
  • Pfizer Ltd
  • GlaxoSmithKline UK Limited
  • Abbvie Ltd
  • Neon Healthcare Ltd
  • AstraZeneca
  • Aventis Pharma ltd t/a Sanofi
  • Ipsen
  • Biogen
  • Takeda UK Ltd
  • Merck Serono Limited
  • Organon Pharmaceuticals UK Ltd
  • Zentiva Pharma UK Ltd
  • Novo Nordisk
  • Novartis Pharmaceuticals UK Ltd
  • Eli Lilly & Company Ltd
  • CST Pharma Limited
  • Gilead Sciences Limited
  • Gedeon Richter UK Ltd
  • Sobi (Swedish Orphan Biovitrum Ltd)
  • Almirall
  • Typharm Ltd
  • UCB Pharma Ltd (primary)
Award value
£480,429,000
Award date
13 February 2023

Contact

Address
2nd Floor Rutland House, Runcorn, WA7 2ES
Contact name
Katie Noonan
Email
[email protected]

Identifiers

Buyer reference
CF-1337600D0O000000rwimUAA
Notice ID
e09b27e8-015d-4066-b22b-0f8de08b4ed6-624220
OCID
ocds-b5fd17-9a77eff1-de9e-4e91-9613-3cf1cd874bb6

Explore related tenders

Other tenders from NHS England

View all →
Secondary Care Medicines Data Pre-Market Engagement£6,750,000
Quality Assurance & Improvement of Structured Learning Placement (SLP) Modules£98,000
Targeted Prostate Cancer Screening Programme - MRI Reporting Service
Targeted Prostate Cancer Screening Programme – PSA Laboratory Processing Service
Strengthening Cultural Capability and Trauma Informed Care in Women’s Health£175,000

External ID: cf-ocds-b5fd17-9a77eff1-de9e-4e91-9613-3cf1cd874bb6 • Added 4 October 2026